June 18, 2025
As with much of the U.S. government, the Food and Drug Administration (FDA) has experienced an increase in uncertainty since the beginning of the year, and it is likely that this uncertainty will persist. In this paper, we examine the data on the PDUFA date misses and the use of advisory committee meetings, comparing the results to historical precedent.
October 16, 2024
The industry’s pipeline is filled with late-stage therapies showing promising data and transformative potential. inThought analysts spotlight potential breakthrough treatments in the MM&M Pipeline Report, providing insight into why these drugs could be life-changing.
October 16, 2024
The industry’s pipeline is filled with late-stage therapies showing promising data and transformative potential. inThought analysts spotlight potential breakthrough treatments in the MM&M Pipeline Report, providing insight into why these drugs could be life-changing.
September 24, 2024
inThought Research announced its artificial intelligence (AI) strategy – to use machine learning and large language models to cut down on tedious tasks in a compliant and secure manner, elevating our partners in the drug discovery industry.
August 13, 2024
inThought today launched its new “Insights Framework.” The Insights Framework enhances these efforts by proactively working with our partners to define key business objectives and map catalysts.
July 30, 2024
inPhronesis, subsidiary of inThought Research, announced today that it is changing its name to inThought Labs. The new name reflects inThought Labs’ commitment to providing innovative and impactful technologies to pharmaceutical clients, and it highlights the increased importance of AI and other technologies to biopharma decision support, medical affairs/communications, and business development.
October 10, 2023
inThought Research and inPhronesis were recently featured on the cover of Healthcare Everything magazine’s 10 best companies in the digital therapeutics market 2023. Read about the history of the two companies and our digital offerings from our President Ben Weintraub.
October 10, 2023
Read inThought’s pick for potential blockbuster drugs that will launch in 2024 in the MM&M Pipeline Report. inThought analysts provide insight into why these drugs will be practice-changing.
inThought Research empowers biopharma leaders with comprehensive strategic insights. We combine Wall Street financial acumen and swiftness, scientific expertise, and advanced AI analytics to navigate the complex landscape of drug development.
© 2025 inThought Research. All Rights Reserved.
As the president of inThought Labs, Chris is focused on constantly improving inVision, the leading competitive and market intelligence platform for the biopharmaceutical industry, to better meet the changing needs of clients.
With 20 years of experience in roles being a consumer of market and competitive information, Chris understands the needs and priorities of clients. Chris was a senior principal and co-founder of inThought, a life science consulting, market research, and analytics firm. Collaborating with Ben Weintraub, Chris also co-founded BiotechTracker, an online tool for investors and precursor to inVision. Previous to inThought, he was a healthcare analyst and co-portfolio manager at two investment firms. Chris served in health care policy roles at the White House Office of Management and Budget. These roles included Medicare Desk Officer at the Office of Information and Regulatory Affairs, where he was responsible for providing recommendations to senior White House policy officials on healthcare policies and regulations.
Chris has a Master in Business Administration from Harvard Business School, a Master in Engineering from Villanova University, and a Bachelor of Science in Engineering from Cornell University. Prior to attending Harvard Business School, Chris served on two U.S. Navy nuclear submarines and at the Pentagon.
